Parameter
| Biomarker | SLC7A11 (xCT) | Full name | Solute Carrier Family 7 Member 11 (xCT) | Molecular Type | Transporter |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Diagnosis, Prediction |
| Disease | Epilepsy | Disease Subtypes | / | ||
| Organ | Brain | Test Sample / Technology Platform | Tumor Tissue (Immunohistochemistry, qPCR) | ||
| Pathobiological Mechanisms | Mediates cystine-glutamate exchange, excessively releases glutamate into the extracellular space, activates excitatory neurons, inducing epilepsy. | ||||
| Clinical Availability Status | Research validation stage | ||||
| Notes and Dynamics | The incidence of epilepsy in glioma patients with high SLC7A11 expression reaches 75%; the specific inhibitor sulfasalazine can reduce seizures. | ||||